Intersect ENT announced that the FDA has approved Propel mini (mometasone furoate), a localized steroid-releasing product for patients with chronic sinusitis.

The Propel mini is a smaller version of Propel that is inserted by a physician following endoscopic sinus surgery.  The implant expands to prop open the sinus, gradually delivers an advanced steroid with anti-inflammatory properties directly to the sinus lining, and then dissolves into the body. This reduces the need for additional surgical procedures and for systemic steroids, which can have serious side effects. Propel mini delivers the same dose of mometasone furoate as provided by Propel, and allows patients with smaller anatomy to benefit from less extensive surgery and improved surgical outcomes.

Propel mini will be offered in select hospitals starting this month and will be launched nationwide in 2013.

For more information call (650) 641-2100 or visit